Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00904202 · ClinicalTrials.gov registry record · Phase 4
A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions
A Phase 4 study of Peripheral Neuropathy and Carpal Tunnel Syndrome, sponsored by Endo Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 62
- Enrollment target
- 7
- Study locations
NCT00904202: Completed Phase 4 study of Peripheral Neuropathy and Carpal Tunnel Syndrome, sponsored by Endo Pharmaceuticals.
NCT00904202 is a Phase 4 study of Peripheral Neuropathy and Carpal Tunnel Syndrome that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 62 participants, below the 78-participant average among 27 other Peripheral Neuropathy trials with a reported enrollment target (21% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00904202, a Phase 4 study of Peripheral Neuropathy and Carpal Tunnel Syndrome, has completed, sponsored by Endo Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 62 participants
- Enrollment target
- 7
- Study locations
Study Summary
Patients with postherpetic neuralgia (PHN), diabetic neuropathy (DN), complex regional pain syndrome (CRPS), carpal tunnel syndrome, HIV neuropathy, idiopathic sensory neuropathy, or other peripheral neuropathy participated in a Phase IV clinical trial to assess the comparative efficacy and safety of Lidoderm monotherapy versus gabapentin monotherapy in treating a diverse group of peripheral neuropathic pain patients.
Conditions Studied
Interventions
- DRUG Placebo Capsules + Placebo Patch
- DRUG Placebo capsules + Lidoderm®
- DRUG Gabapentin + Placebo
- DRUG Gabapentin + Lidoderm®
- DRUG Gabapentin 300 mg capsules 1800 mg/day + placebo patch
Study Locations (7)
Alabama
- - Birmingham
- - Hueytown
New York
- - New York
- - Rochester
Arizona
- - Phoenix
Florida
- - Pembroke Pines
Pennsylvania
- - Altoona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2003-01 |
| Phase | Phase 4 |
What the finished NCT00904202 record still lists
NCT00904202 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 78-participant average among 27 other Peripheral Neuropathy trials with a reported enrollment target (21% lower).
The record links to 7 conditions, with Peripheral Neuropathy appearing as the primary indexed condition, and to 5 interventions - of which Placebo Capsules + Placebo Patch is the first listed.
NCT00904202 lists 7 locations in 5 states (Alabama, New York, Arizona).
Frequently Asked Questions
What is clinical trial NCT00904202 about?
NCT00904202 is a clinical study titled "A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions". Patients with postherpetic neuralgia (PHN), diabetic neuropathy (DN), complex regional pain syndrome (CRPS), carpal tunnel syndrome, HIV neuropathy, idiopathic sensory neuropathy, or other peripheral neuropathy participated in a Phase IV clinical trial to assess the comparative efficacy and safety o...
What is the current status of trial NCT00904202?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 62 participants. The study started on 2003-01.
What conditions does trial NCT00904202 study?
This clinical trial studies the following conditions: Peripheral Neuropathy, Carpal Tunnel Syndrome, Diabetic Neuropathy, Post Herpetic Neuralgia, Complex Regional Pain Syndrome.
What interventions are being tested in trial NCT00904202?
The interventions under investigation include: Placebo Capsules + Placebo Patch (DRUG), Placebo capsules + Lidoderm® (DRUG), Gabapentin + Placebo (DRUG), Gabapentin + Lidoderm® (DRUG), Gabapentin 300 mg capsules 1800 mg/day + placebo patch (DRUG).
Who is sponsoring clinical trial NCT00904202?
This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00904202 being conducted?
This trial has 7 study locations across Alabama, Arizona, Florida, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Neuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00904202's enrollment target sits among peer trials
62 10th of 27 higher than 17 of 27 other Peripheral Neuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral Neuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Prospective Natural History and Outcome Measure Discovery Study of Charcot-Marie-Tooth Disease, Type 4J
RECRUITING
-
A Causative Role for Amylin in Diabetic Peripheral Neuropathy
RECRUITING
-
Innovative Treatment of Chemotherapy-Induced Painful Peripheral Neuropathy in Adolescents and Young Adults With Cancer: A Two Arm Pilot Study
RECRUITING · NA
-
Replexa+ Shortwave Diathermy Device for Patients Diagnosed With Peripheral Artery Disease and Peripheral Neuropathy
RECRUITING · NA
-
DoD AtMS for Posttraumatic Peripheral Neuropathic Pain
RECRUITING · NA
-
Intermittent Dosing of Dorsal Root Ganglion Stimulation as an Alternate Paradigm to Continuous Low-Frequency Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia